Clinical trial
A Phase 1/2, Randomized, Observer-Blind, Active-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity and Immunogenicity of mRNA-1468, a Candidate Vaccine to Prevent Herpes Zoster (HZ) in Healthy Adults ≥50 Years of Age
NCT05701800 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Randomized, Observer-Blind, Active-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity and Immunogenicity of mRNA-1468, a Candidate Vaccine to Prevent Herpes Zoster (HZ) in Healthy Adults ≥50 Years of Age
- Lead sponsor
- ModernaTX, Inc.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- January 23, 2023
- Completion date
- December 31, 2025
- Enrollment
- 659 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.